Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Pelt – page 69

870 clinical trials in Pelt, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Pelt at a glance
870
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

870 trials in Pelt

Open in trial search

Partial seizures

Not recruiting

Study of EQU-001 and Placebo for Patients with Uncontrolled Focal Seizures in Epilepsy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:Equilibre Biopharmaceuticals B.V.

Colon cancer stage III+1

Not recruiting

Study on Aspirin for Preventing Recurrence and Improving Survival in Patients with Stage II and III Colon Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

COVID-19

Not recruiting

Study on Montelukast for COVID-19 Patients at Higher Risk in Primary Care

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Montelukast
  • Sponsor:Universiteit Maastricht

Colon cancer stage III+1

Not recruiting

Study on Aspirin for Preventing Recurrence and Improving Survival in Patients with Resected Colon Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Antwerp University Hospital

Dry mouth

Not recruiting

Study on Pilocarpine Hydrochloride for Dry Mouth in Adults with Life-Limiting Conditions or Frailty

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pilocarpine Hydrochloride
  • Sponsor:University Hospital Maastricht

Study on Reducing Bleeding by Omitting Aspirin in Patients with Non-ST Elevation Acute Coronary Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Amsterdam UMC Stichting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Embolism

Not recruiting

Study on REGN9933 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Dyspepsia

Not recruiting

Study on Reducing Proton Pump Inhibitor Use in Patients with Heartburn, Reflux, or Dyspepsia: Comparing On-Demand Use, Alginate Therapy, and Gradual Dose Reduction

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Aluminium Oxide
  • Sponsor:UZ Leuven

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Multiple sclerosis+4

Not recruiting

Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Antwerp University Hospital

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Pelt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing forms of multiple sclerosis, evaluating novel therapeutic approaches and comparing treatment efficacies. Studies investigate various medications including frexalimab and remibrutinib against established treatments.

  • Relapsing MS Therapies
  • Disease Progression Analysis
  • Treatment Comparison Studies

Several trials aim to assess reduction in relapse frequency and improvement in patient outcomes.

02 Progressive MS Studies

Dedicated research into primary progressive multiple sclerosis (PPMS) and secondary progressive forms, exploring innovative treatments and their impact on disease progression. Studies evaluate higher-dose protocols and long-term effectiveness.

  • Disability Progression Markers
  • Novel Treatment Approaches
  • Long-term Safety Assessments

Focus on developing treatments to delay disability progression and improve patient mobility.

03 Advanced Therapeutic Studies

Investigation of innovative treatment modalities including BTK inhibitors and combination therapies. Research includes assessment of brain remyelination and neurodegeneration markers.

  • Biomarker Analysis
  • Pharmacokinetic Studies
  • Safety Monitoring

Comprehensive evaluation of new therapeutic approaches using advanced imaging and clinical assessments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.